Medicaid freezes GLP‑1 coverage

Pennsylvania Medicaid recently stopped covering GLP‑1 drugs for obesity after program costs jumped from $233 million to $1.3 billion over three years, a move that highlights how reimbursement decisions are reshaping access. (The Philadelphia Inquirer reported the coverage halt and the specific cost figures driving the policy change.) (Pennsylvania Medicaid stopped covering GLP-1s for obesity this year, but it's not all savings)